69.51MMarket Cap1.32P/E (TTM)
1.860High1.800Low94.84KVolume1.840Open1.845Pre Close173.21KTurnover0.25%Turnover Ratio1.32P/E (Static)37.78MShares3.87052wk High0.95P/B68.63MFloat Cap1.35052wk Low--Dividend TTM37.30MShs Float150.000Historical High--Div YieldTTM3.25%Amplitude1.150Historical Low1.826Avg Price1Lot Size
Scynexis Stock Forum
NEWS
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
SCYNEXIS, Inc. (SCYX) announces the presentation of preclinical efficacy data on SCY-247 at ECCMID 2024, focusing on addressing systemic fungal diseases and invasive fungal infections. SCY-247 shows promise in overcoming drug-resistant infections, particularly against Candida auris.
Benzinga· just
No comment yet